Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.85 USD | -0.87% | -10.69% | -30.81% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | - | 957.8 | 639.3 | 1,010 | 738.3 | - | - |
Enterprise Value (EV) 1 | - | 816.5 | 579.3 | 943.3 | 772.8 | 499 | 408.3 |
P/E ratio | -2.53 x | -11.6 x | -5.89 x | -9.17 x | -5.31 x | -5.25 x | -4.8 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 25.9 x | 25.7 x | 27.6 x | 23.6 x | 23.3 x | 23.2 x |
EV / Revenue | - | 22 x | 23.3 x | 25.8 x | 24.7 x | 15.8 x | 12.8 x |
EV / EBITDA | - | -14.3 x | -5.29 x | -8.44 x | -4.74 x | -2.57 x | -1.86 x |
EV / FCF | - | - | - | -7.89 x | -5.64 x | -3.56 x | -2.63 x |
FCF Yield | - | - | - | -12.7% | -17.7% | -28.1% | -38.1% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | - | 87,546 | 88,177 | 101,990 | 106,846 | - | - |
Reference price 2 | 11.44 | 10.94 | 7.250 | 9.900 | 6.850 | 6.850 | 6.850 |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 37.04 | 24.86 | 36.53 | 31.31 | 31.62 | 31.79 |
EBITDA 1 | - | -57.29 | -109.5 | -111.8 | -163.1 | -193.8 | -219.2 |
EBIT 1 | - | -58.19 | -111.1 | -114.2 | -151.5 | -163 | -184.5 |
Operating Margin | - | -157.09% | -446.79% | -312.57% | -483.97% | -515.59% | -580.39% |
Earnings before Tax (EBT) 1 | - | -57.94 | -108.1 | -101.6 | -137.6 | -147.6 | -155.4 |
Net income 1 | -51.97 | -58.24 | -108.2 | -101.7 | -140.4 | -153.4 | -172.9 |
Net margin | - | -157.21% | -435.14% | -278.54% | -448.36% | -485.19% | -543.99% |
EPS 2 | -4.530 | -0.9400 | -1.230 | -1.080 | -1.290 | -1.306 | -1.426 |
Free Cash Flow 1 | - | - | - | -119.5 | -137 | -140 | -155.5 |
FCF margin | - | - | - | -327.18% | -437.62% | -442.73% | -489.14% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 5.716 | 5.758 | 5.771 | 6.92 | 6.411 | 5.766 | 14.6 | 10.73 | 5.431 | 6.471 | 8.198 | 8.028 | 8.597 | 7.588 | 6.962 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -21.98 | -25.38 | -25.2 | -29.92 | -30.57 | -30.29 | -23.25 | -25.63 | -35.01 | -42.26 | -36.95 | -37.21 | -36.22 | -38.03 | -38.63 |
Operating Margin | -384.6% | -440.76% | -436.7% | -432.41% | -476.79% | -525.25% | -159.25% | -238.78% | -644.69% | -652.99% | -450.71% | -463.51% | -421.33% | -501.28% | -554.76% |
Earnings before Tax (EBT) 1 | -21.87 | -25.21 | -24.86 | -29.05 | -29.01 | -28.01 | -20.65 | -22.24 | -30.72 | -37.87 | -33.82 | -33.54 | -33.14 | -36.51 | -37.22 |
Net income 1 | -22.05 | -25.21 | -24.86 | -29.05 | -29.06 | -28.01 | -20.71 | -22.26 | -30.76 | -37.91 | -34.53 | -34.26 | -34.06 | -36.51 | -37.22 |
Net margin | -385.69% | -437.79% | -430.74% | -419.8% | -453.28% | -485.74% | -141.87% | -207.45% | -566.43% | -585.91% | -421.19% | -426.81% | -396.26% | -481.17% | -534.59% |
EPS 2 | -0.2600 | -0.2900 | -0.2800 | -0.3300 | -0.3300 | -0.3200 | -0.2300 | -0.2300 | -0.3000 | -0.3500 | -0.3200 | -0.3143 | -0.3057 | -0.3075 | -0.3200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/11/22 | 8/10/22 | 11/10/22 | 3/27/23 | 5/9/23 | 8/7/23 | 11/8/23 | 3/18/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 34.5 | - | - |
Net Cash position 1 | - | 141 | 60 | 66.4 | - | 239 | 330 |
Leverage (Debt/EBITDA) | - | - | - | - | -0.2113 x | - | - |
Free Cash Flow 1 | - | - | - | -120 | -137 | -140 | -156 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | 7.69 | 1.53 | 3.65 | 4.2 | 5.1 |
Capex / Sales | - | - | 30.94% | 4.18% | 11.66% | 13.28% | 16.04% |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.81% | 738M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- TNGX Stock
- Financials Tango Therapeutics, Inc.